Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A
Abstract
The activities of MYC, the androgen receptor, and its associated pioneer factors demonstrate substantial reprogramming between early and advanced prostate cancer. Although previous studies have shown a shift in cellular metabolic requirements associated with prostate cancer progression, the epigenetic regulation of these processes is incompletely described. Here, we have integrated chromatin immunoprecipitation sequencing (ChIP-seq) and whole-transcriptome sequencing to identify novel regulators of metabolism in advanced prostate tumors characterized by elevated MYC activity.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 01, 2022
- Source ID
- 10.1007/s12672-022-00565-3
Entities
People
- Adam G Sowalsky
- Anson T. Ku
- Brian J. Capaldo
- Elaine M. Jagoda
- Falguni Basuli
- Karen Wong
- Kathleen Kelly
- Lei Fang
- Margaret E. White
- Nichelle C. Whitlock
- Peter L Choyke
- Scott Wilkinson
- Shana Y. Trostel
- Supreet Agarwal
- Zhen-dan Shi
Organizations
- Congressionally Directed Medical Research Programs
- National Institutes of Health
- Prostate Cancer Foundation